Novo Nordisk shares dropped 8% on Tuesday after its rival Eli Lilly and Co. published positive trial results.
The United States medicine company reported last week positive results from a late-stage trial regarding its oral weight loss drug orforglipron. Following this development, Novo Nordisk marked a fall, including other healthcare stocks, after the European market opening.
The company's shares were down by 7.43% at 11:09 am CET, selling at 389.30 Danish Krone, while Eli Lilly gained 0.62% to $823.12 in the premarket in New York.